Biohaven .(BHVN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments • Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 • Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform advancing multiple new targets and reported positive interim data from its lead investigational drug in an ongoing Phase 1 study of BHV-1300: ◦ The Company reported dose-dependent and rapid IgG reductions in its ongo ...